Treatment with dupilumab for acute COVID-19 was also associated with a larger decline in eotaxin, IL-12p40, IP-10, and FLT3, and with an increase in the anti-inflammatory cytokine IL-1Ra. Here, CCL11 is linked to COVID-19.